AllSight
Companies · LLY · Pharmaceutical Preparations

ELI LILLY & Co (LLY)

ELI LILLY & Co (LLY) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.

ELI LILLY & Co (LLY) stock — financials & valuation

Key numbers for ELI LILLY & Co (LLY): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.

AllSight quality score: 58/100 — a percentile rank of ELI LILLY & Co’s fundamentals against Manufacturing peers, weakest on valuation. A quality ranking, not a price prediction.

Market cap$1.0T
P / E38.4×
P / S12.9×
EV / EBITDA25.7×
Gross margin83.4%
Operating margin42.2%
Net margin33.5%
Return on equity78.8%
ROIC33.5%
Revenue growth49.6%
Debt / equity1.6×
Dividend yield0.6%

Is ELI LILLY & Co overvalued? P/E looks undervalued vs its 5-year range; P/S looks fair vs its 5-year range; EV/EBITDA looks undervalued vs its 5-year range; P/B looks fair vs its 5-year range.

Independent of the events above — derived from ELI LILLY & Co’s own financial statements and shown as context, never as advice.

Aug 5, 2026
Revenue and profit crushed expectations; deal charges trim the EPS outlook.
Related companies in Pharmaceutical Preparations
Open live on AllSight — the whole market, decoded →

About AllSight · Editorial standards & method · Contact